Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Jul 21, 2021 2:02pm
132 Views
Post# 33582102

RE:RE:RE:And don't forget the insider trading

RE:RE:RE:And don't forget the insider trading
Accountprince wrote: This came out of the blue for non-insider shareholders but I'm sure it was planned.  It seems our management team is only in tune with spreading the wealth amongst the privileged.  I hear you about other companies promoting themselves and then doing a share issue.  Novel idea for this stock.

Our person(s) in charge of financing don't seem to care at all about getting prudent deals done.  Let's go public in US - nothing done.  We'll sell small portion of Dialco - nothing done.  We're trading in the low 50's.  Let's drop it at the close and announce overnight a bought deal at 40 cents.  Pure insanity but perhaps Anonymous needed reloading.  And don't forget the "President's List" for 10% of the deal - why is that part of the bought dealThey couldn't even do a deal at the price we had been trading at - a modest $.52?  Pathetic.

Looked great when we hired someone familiar with the public markets to head up our financing efforts.  Result - we are now issuing paper at half the price we had been trading at the beginning of 2020 with MULTIPLE achievements since then.  Epic fail!!  



100% agree !!


Also Compensation Options to the Underwriters (Paradigm - from Seto's resume)  @ .485 issued at 6.5% of issuance, in addition to the 6.5% cash commission. Easch compensation Option is exercisable for one Common share, (not 1/2 for one) for a period ot two years.

No apparent conflict of interest there ;)

Very Alswellian.

MM

<< Previous
Bullboard Posts
Next >>